4-hydroxy-2-nonenal and Diabetic-Nephropathies

Zinc deficiency during diabetes projects a role for zinc nutrition in the management of diabetic nephropathy. The current study explored whether zinc supplementation protects against diabetic nephropathy through modulation of kidney oxidative stress and stress-induced expression related to the inflammatory process in streptozotocin-induced diabetic rats. Groups of hyperglycemic rats were exposed to dietary interventions for 6 weeks with zinc supplementation (5 times and 10 times the normal level). Supplemental-zinc-fed diabetic groups showed a significant reversal of increased kidney weight and creatinine clearance. There was a significant reduction in hyperlipidemic condition along with improved PUFA:SFA ratio in the renal tissue. Expression of the lipid oxidative marker and expression of inflammatory markers, cytokines, fibrosis factors and apoptotic regulatory proteins observed in diabetic kidney were beneficially modulated by zinc supplementation, the ameliorative effect being concomitant with elevated antiapoptosis. There was a significant reduction in advanced glycation, expression of the receptor of the glycated products and oxidative stress markers. Zinc supplementation countered the higher activity and expression of polyol pathway enzymes in the kidney. Overexpression of the glucose transporters, as an adaptation to the increased need for glucose transport in diabetic condition, was minimized by zinc treatment. The pathological abnormalities in the renal architecture of diabetic animals were corrected by zinc intervention. Thus, dietary zinc supplementation has a significant beneficial effect in the control of diabetic nephropathy. This was exerted through a protective influence on oxidative-stress-induced cytokines, inflammatory proliferation and consequent renal injury.

Topics: Aldehydes; Animals; Antioxidants; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dietary Supplements; Enzymes; Fatty Acids; Female; Kidney; Organ Size; Oxidative Stress; Polymers; Rats, Wistar; Streptozocin; Transcriptome; Zinc

Diabetic nephropathy (DN) is an acute and serious diabetic complication characterized by renal hypertrophy and renal fibrosis with the expansion of extracellular matrices. Diabetic nephropathy has become a major cause of end-stage kidney disease. Sanziguben Granule (SZGB) is a compound prescription which has been widely applied in clinical medicine for the prevention and treatment of diabetic nephropathy as well as for acute and chronic kidney injuries. However, the mechanism of protective effects of SZGB in DN remains unclear.. In this research, we investigated the effects of SZGB on renal interstitial fibrosis, antioxidant proficiency, and apoptosis in streptozotocin (STZ)-induced diabetic rats. Diabetic rats were prepared by performing a right uninephrectomy along with a single intraperitoneal injection of STZ. Rats were divided into six groups including sham, DN, SZGB-D, SZGB-Z, SZGB-G and fosinopril. SZGB and fosinopril were given to rats by gavage for 12 weeks. Samples from urine, blood and kidneys were collected for biochemical, histological, immunohistochemical and western blot analyses.. We found that rats treated with SZGB showed reduced 24-h urinary protein excretion along with reduced serum total cholesterol (TC) and triglyceride (TG) levels. SZGB was also shown to prevent the disruption of catalase activity and reduce serum urea, creatinine, and renal malondialdehyde while increasing glutathione levels. Moreover, SZGB administration markedly improved the expression levels of E-cadherin, 4-HNE, Nrf2, HO-1, and Bcl-2, while it decreased the expression levels of Vimentin, α-SMA and Cleaved caspase-3 in the kidneys of diabetic rats. The renoprotective effects of SZGB was believed to be mediated by its antioxidant capacity, and SZGB treatment attenuated renal fibrosis through stimulating the nuclear factor erythroid-2-related factor 2 (Nrf2) signaling pathway in the diabetic kidneys.. Therefore, it is suggested that SZGB can restrain epithelial-mesenchymal transition (EMT) through stimulating the Nrf2 pathway, which improves renal interstitial fibrosis in DN.

Topics: Aldehydes; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drugs, Chinese Herbal; Fibrosis; Gene Expression Regulation; Male; NF-E2-Related Factor 2; Oxidative Stress; Proteinuria; Rats; Rats, Sprague-Dawley; Streptozocin

To investigate 4-HNE expression in diabetic rat kidneys and the protective effect of probucol.. Diabetic rat models were established. Diabetic rats with successful modeling were randomly divided into the diabetic group (group D) and probucol treated group (group P). Normal rats were put into the control group (group C). Rats in group P were treated with probucol (110 mg/kg day), and rats in groups D and C were given equal volume of water instead. Serum creatinine (SCr), urea nitrogen (BUN), triglyceride (TG), total cholesterol (TC), and 24-h urinary protein were measured at the 4th, 8th, and 12th weeks. Periodic acid-schiff (PAS) staining and hematoxylin-eosin (HE) staining were used to evaluate the renal pathological changes. The immunohistochemistry and Western-blot were used to detect 4-HNE expression in renal tissue.. The SCr, BUN, TG, TC, and 24-h urinary protein in group D increased in the 4th, 8th, and 12th weeks and were higher than those in group C (P < 0.05). The SCr, BUN, TG, TC, and 24-h urinary protein in group P decreased compared to group D (P < 0.05). Pathological kidney changes in group D were more serious than those in group P. The level of 4-HNE expression in group D significantly increased at the 4th, 8th, and 12th weeks and were higher than those in group C (P < 0.05). In the kidneys treated with probucol, the level of 4-HNE significantly decreased compared to group D (P < 0.05).. Probucol can protect the diabetic kidney by decreasing 4-HNE expression and lipid peroxidation levels.

Topics: Aldehydes; Animals; Antioxidants; Biomarkers; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Immunohistochemistry; Lipid Peroxidation; Male; Oxidative Stress; Probucol; Rats; Rats, Wistar

Although recent studies have proven that renin-angiotensin system (RAS) blockades retard the progression of diabetic nephropathy, the detailed mechanisms of their reno-protective effects on the development of diabetic nephropathy remain uncertain. In rodent models, it has been reported that reactive oxygen species (ROS) are important for intrarenal angiotensinogen (AGT) augmentation in the progression of diabetic nephropathy. However, no direct evidence is available to demonstrate that AGT expression is enhanced in the kidneys of patients with diabetes. To examine whether the expression levels of ROS- and RAS-related factors in kidneys are increased with the progression of diabetic nephropathy, biopsied samples from 8 controls and 27 patients with type 2 diabetes were used. After the biopsy, these patients were diagnosed with minor glomerular abnormality or diabetes mellitus by clinical and pathological findings. The intensities of AGT, angiotensin II (Ang II), 4-hydroxy-2-nonenal (4-HNE), and heme oxygenase-1 (HO-1) were examined by fluorescence in situ hybridization and/or immunohistochemistry. Expression levels were greater in patients with diabetes than in control subjects. Moreover, the augmented intrarenal AGT mRNA expression paralleled renal dysfunction in patients with diabetes. These data suggest the importance of the activated oxidative stress/AGT/RAS axis in the pathogenesis of diabetic nephropathy.

Topics: Adult; Aldehydes; Angiotensinogen; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Heme Oxygenase-1; Humans; Kidney; Male; Oxidative Stress; Reactive Oxygen Species; Renin-Angiotensin System

To investigate the effect of the GPx1-mimetic ebselen on diabetes-associated atherosclerosis and renal injury in a model of increased oxidative stress.. The study was performed using diabetic apolipoprotein E/GPx1 (ApoE(-/-)GPx1(-/-))-double knockout (dKO) mice, a model combining hyperlipidemia and hyperglycemia with increased oxidative stress. Mice were randomized into two groups, one injected with streptozotocin, the other with vehicle, at 8 weeks of age. Groups were further randomized to receive either ebselen or no treatment for 20 weeks.. Ebselen reduced diabetes-associated atherosclerosis in most aortic regions, with the exception of the aortic sinus, and protected dKO mice from renal structural and functional injury. The protective effects of ebselen were associated with a reduction in oxidative stress (hydroperoxides in plasma, 8-isoprostane in urine, nitrotyrosine in the kidney, and 4-hydroxynonenal in the aorta) as well as a reduction in VEGF, CTGF, VCAM-1, MCP-1, and Nox2 after 10 weeks of diabetes in the dKO aorta. Ebselen also significantly reduced the expression of proteins implicated in fibrosis and inflammation in the kidney as well as reducing related key intracellular signaling pathways.. Ebselen has an antiatherosclerotic and renoprotective effect in a model of accelerated diabetic complications in the setting of enhanced oxidative stress. Our data suggest that ebselen effectively repletes the lack of GPx1, and indicate that ebselen may be an effective therapeutic for the treatment of diabetes-related atherosclerosis and nephropathy. Furthermore, this study highlights the feasibility of addressing two diabetic complications with one treatment regimen through the unifying approach of targeted antioxidant therapy.

Topics: Aldehydes; Animals; Antioxidants; Apolipoproteins E; Atherosclerosis; Azoles; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Nephropathies; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Isoindoles; Kidney; Male; Mice; Mice, Knockout; Organoselenium Compounds; Reactive Oxygen Species; Tyrosine; Vascular Cell Adhesion Molecule-1

Oxidative stress has been suggested to play a main role in the pathogenesis of type 2 diabetes mellitus and its complications. As a consequence of this increased oxidative status, a cellular-adaptive response occurs requiring functional chaperones, antioxidant production, and protein degradation. This study was designed to evaluate systemic oxidative stress and cellular stress response in patients suffering from type 2 diabetes-induced nephropathy and in age-matched healthy subjects. Systemic oxidative stress has been evaluated by measuring advanced glycation end-products (pentosidine), protein oxidation (protein carbonyls [DNPH]), and lipid oxidation (4-hydroxy-2-nonenal [HNE] and F2-isoprostanes) in plasma, lymphocytes, and urine, whereas the lymphocyte levels of the heat shock proteins (Hsps) heme oxygenase-1 (HO-1), Hsp70, and Hsp60 as well as thioredoxin reductase-1 (TrxR-1) have been measured to evaluate the systemic cellular stress response. We found increased levels of pentosidine (P < 0.01), DNPH (P < 0.05 and P < 0.01), HNE (P < 0.05 and P < 0.01), and F2-isoprostanes (P < 0.01) in all the samples from type 2 diabetic patients with nephropathy with respect to control group. This was paralleled by a significant induction of cellular HO-1, Hsp60, Hsp70, and TrxR-1 (P < 0.05 and P < 0.01). A significant upregulation of both HO-1 and Hsp70 has been detected also in lymphocytes from type 2 diabetic patients without uraemia. Significant positive correlations between DNPH and Hsp60, as well as between the degree of renal failure and HO-1 or Hsp70, also have been found in diabetic uremic subjects. In conclusion, patients affected by type 2 diabetes complicated with nephropathy are under condition of systemic oxidative stress, and the induction of Hsp and TrxR-1 is a maintained response in counteracting the intracellular pro-oxidant status.

Topics: Aldehydes; Arginine; Chaperonin 60; Diabetic Nephropathies; F2-Isoprostanes; Female; Heat-Shock Response; Heme Oxygenase-1; HSP70 Heat-Shock Proteins; Humans; Lymphocytes; Lysine; Male; Middle Aged; Oxidative Stress; Protein Carbonylation; Renal Insufficiency; Thioredoxin Reductase 1

Accumulation of Advanced Lipoxidation End-products (ALE), such as MDA- and HNE-protein adducts, and Advanced Glycation End-products, such as carboxymethyl-lysine (CML), are probably involved in the development of diabetic nephropathy. In this study the effect of some antioxidant treatments (oxerutin, N-acetylcysteine, taurine and N-acetylcysteine+taurine) on kidney lipoxidative damage has been evaluated by immunohistochemistry in streptozotocined rats. Diabetic rats showed marked glomerular positivity for ALE, while the samples from Control rats were negative. All treatments except taurine were able to protect the glomeruli from ALE accumulation; the failure of taurine may be due to residual oxidative properties of its derivatives. These data are consistent with those of our previous study, which showed that all the antioxidants used except taurine protected the glomeruli from diabetes-induced enlargement, increased apoptotic rate, decreased cell density and CML accumulation. These data attest to a role of glycoxidative and lipoxidative damage in diabetes-dependent damage of the kidney, and indicate that specific antioxidants can prevent or attenuate diabetic nephropathy.

Topics: Acetylcysteine; Aldehydes; Animals; Apoptosis; Cell Division; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glycation End Products, Advanced; Hydroxyethylrutoside; Immunohistochemistry; Kidney Glomerulus; Lipid Peroxidation; Lysine; Male; Rats; Rats, Wistar; Taurine